Yet , ONJ due to molecular-targeted (anti-angiogenic) agents, just like sunitinib (a multikinase inhibitor) and bevacizumab [a monoclonal antibody targeting vascular endothelial expansion factor (VEGF)], has recently recently been reported in patients which have never received bisphosphonates (810)
Yet , ONJ due to molecular-targeted (anti-angiogenic) agents, just like sunitinib (a multikinase inhibitor) and bevacizumab [a monoclonal antibody targeting vascular endothelial expansion factor (VEGF)], has recently recently been reported…